Advertisement

Volume 129, Issue 19

Cover Figure: Critical role of neutrophils in mechanism of action of anti-CD20 antibodies. See the article by Valgardsdottir et al.

WASHINGTON, May 11, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies
Valgardsdottir et al elucidate how anti-CD20 monoclonal antibodies (mAbs) function, and they clarify the critical role of neutrophils in the mechanism of action of antibody immunotherapy. Neutrophils do not kill chronic lymphocytic leukemia (CLL) cells opsonized with CD20 mAbs, but they remove mAb-CD20 complexes from B cells by a process termed trogocytosis.

Vitamin B12 deficiency from the perspective of a practicing hematologist
This article offers an up-to-date review of vitamin B12 deficiency and comprehensively highlights its diagnosis and treatment.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Barr et al show that dose and schedule adherence of the Bruton tyrosine kinase inhibitor ibrutinib is critical for therapeutic outcome in patients with CLL.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Tout and colleagues clarify the heterogeneity of response to rituximab therapy in patients with diffuse large B-cell lymphoma (DLBCL) by demonstrating a relationship between baseline total metabolic tumor volume, rituximab exposure, and therapeutic outcome.

Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML
Liyanage et al demonstrate that acute myeloid leukemia (AML) cells exhibit increased mitochondrial DNA (mtDNA) content and that 2ʹ,3ʹ-dideoxycytidine (ddC), a clinically available inhibitor of mtDNA biosynthesis, selectively kills leukemia cells.

Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease–associated thrombosis in mice
Yang et al explore the effects of the uremic toxin indoxyl sulfate as a trigger of platelet hyperactivity in chronic kidney disease.

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
This study by Schroeder et al demonstrates that single-agent plerixafor mobilizes a graft with plasmacytoid dendritic cell progenitors (pre-pDCs) and mature pDCs along with CD34+ hematopoietic progenitor cells.

Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients
Cooper et al report clonal dynamics and diversity in a cohort of patients with adenosine deaminase–deficient severe combined immunodeficiency (ADA-SCID) after retroviral gene therapy.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia
Fischer et al present efficacy and safety data from a preliminary study of first-line venetoclax and obinutuzumab in older CLL patients with comorbidities.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.